Brendan Finnerty

Brendan Finnerty is a Senior Associate Scientist at Vividion Therapeutics, Inc., where responsibilities include high-throughput screening assays for protein binding and evaluating protein degradation to identify novel substrates targeting 'undruggable' disease-driven proteins. Prior experience includes serving as an Associate Scientist at Bristol Myers Squibb, focusing on similar high-throughput screening methodologies. Brendan's research background also includes work as a Graduate Student Researcher at Hockemeyer Lab, UC Berkeley, investigating the role of POT1 mutations in tumorigenesis, and as a Research Associate at Advanced Cellular Dynamics, where duties involved oncogene compounds and small molecule screening. Brendan holds a Master of Science in Biomedical Science with a concentration in Stem Cell Science from San Francisco State University and a Bachelor of Science in Biology from UC San Diego.